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In this improved reversed-phase liquid-chromatographic procedure for determination of mexiletine in plasma, mexiletine and an internal standard, chlorodisopyramide, are extracted with methylene chloride from 0.5 mL of serum or plasma; the extract isthen concentratedand injected onto a C,8 chromatographic column. Mexiletine in the column effluent is detected by monitoring absorbance at 210 nm. It is quantified by use of mexiletine-internal standard peak-height ratios.
The relation between this ratio and mexiletine concentration is linear from 0.1 to 5.0 mg/L. The lower limit of detection is about 50 ig/L. At a mexiletine concentration of 2.0 mg/L in serum,intrarun precision (CV) is 2.9% and inter-run precision is 5.9%; at 0.5 mg/L, these CV5 are 5.7% and 9.6%, respectively. Analytical recovery of added mexitetine in serum is 68-88%. Therapeutic concentrations of some commonly administered drugs in patients' specimens did not interfere. In serum from 38 patients receiving mexiletine for cardiac arrhythmia, concentrations measured by this method correlated with therapeutic efficacy.
Mexiletine,
1-(2,6-dimethylphenoxy)-2-aminopropane, is a class I antiarrhythmic agent for treatment of ventricular arrhythmias.
It currently is undergoing trials in the United States. A primary amine similar in chemical structure and electrophysiological action to lidocaine, it acts by depressing the maximal rate of depolarization in atrial, ventricular, and Purkinje cells (1-3). Unlike lidocaine, mexiletine can be administered either orally or intravenously. It appears to be effective in 60 to 80% of patients with ventricular arrhythmias refractory to treatment by other drugs (4) (5) (6) . Its optimal concentration range in serum has been defined as 0.75-2.0 mg/L (7, 8) ; therefore its use will require careful monitoring to enhance efficacy and avoid toxicity. Several gas-chromatographic methods for measurement of mexiletine in serum have been reported (9-16). Of the two previously published "high-performance" liquid-chromatographic procedures for mexiletine, one (17) requires derivatization of the sample, multiple sample extractions, and a chromatographic enrichment system. Such complexity makes this assay impractical for most clinical laboratories. The other such procedure (18) is too insensitive, imprecise, and susceptible to interferences for routine use.
Here we report our liquid-chromatographic procedure for sensitive, specific, and precise determination of mexiletine. The necessary pump, column, and detector are available in most clinical laboratories doing liquid-chromatographic analyses.
Materials and Methods

Apparatus.
We The stock solution of mexiletine contained 1.0 g of the free base per liter. It was prepared by dissolving 12.0 mg of mexiletine HC1 (a gift from Boehringer Ingelheim, Ltd., Richfield, CT 06877) in 10.0 mL of water. Working standard, 1.0 mg/L, was prepared by diluting 0.25 mL of stock mexiletine to a total volume of 250 mL with sodium carbonate buffer (0.1 mol/L, pH 10.4). Stock and working mexiletine solutions are stable for at least six months at 4 #{176}C. Serum controls, 0.5 and 2.0 mg/L, were prepared by making appropriate dilutions of stock mexiletine in bovine serum (Pel-Freez Biologicals, Rogers, AR 72756). Aliquots (0.5 mL) of control sera, pipetted into disposable 16 x 125 mm glasstubes and stored at -20 #{176}C, are stable for at least six months.
Stock chlorodisopyramide (a gift from G. D. Searle Co., Skokie, IL 60077), 1.0 g/L, was prepared by dissolving 10mg of free base in 10.0 mL of methanol (stable for at least two years at -20 #{176}C). A working solution of internal standard (40 mgfL) was prepared by diluting 0.40 mL of stock chlorodisopyramide in water to a total volume of 10 mL. Such a solution is stable for at least six months at 4 #{176}C.
Methylene chloride and acetonitrile were glass distilled (Burdick and Jackson Laboratories, Inc.,Muskegon, MI 49442). All other chemicals were reagent grade.
Procedure. Pipet 0. We determined analytical recovery of mexiletine and internal standard from serum by comparing the peak heights of extracted samples with those of equivalent and from 72% to 87% for chlorodisopyramide (n = 8) (Table   1 ). We considered these recoveries adequate. Any further increase in recovery produced by an additional extraction would not improve the sensitivity of the procedure significantly.
Precision was determined at mexiletine concentrations of 0.5 and 2.0 mg/L (Table 2) . Intrarunprecision was determined by analyzing five samples of the same specimen. Inter-runprecision was determined by analyzing 18 samples from a control pool over a period of more than seven months.
We evaluated the possibility of interference by other drugs by adding 2 mg of mexiletine per liter to plasma samples containing known concentrations of any one of various drugs (Table 3) . Because these samples were from patients actually taking these drugs, interferences from drug metabolites, if any, would also be detected. Neither this study nor analyses of more than 50 clinical specimens revealed any drug interfering with this procedure. As shown in Figure 3 , 82% of the patients studied had their arrhythmia controlled by mexiletine without side effects. In 87% of these controlled patients, the mexiletine 
Discussion
The absorbance of mexiletine at 260 nm is low, but increases greatly at wavelengths lower than 225 nm. We chose to use the wavelength 210 nm for this procedure, because the small inflection in the spectrum at this wavelength lessens the effect of small differences in wavelength setting on the absorbance measured. Sensitivity at 210 nm is 30-to 40-fold greater than at 261 nm, the wavelength used in a previously published procedure (18) . In addition, interferences from procainamide and other drugs are greatly diminished at 210 nm as compared with 260 nm.
The mobile phase is qualitatively the same combination used in this laboratory for several liquid-chromatographic procedures (19). We adjusted the acetonitrile concentration to optimize the capacity factor and assay time for the mexiletine method. The structural isomer of mexiletine, 1-(2,4-dimethylphenoxy)-2-aminopropane (K#{246} 768), was unsatisfactory as an internal standard because of differences in its extraction characteristics. In addition, we find its retention time on C18 columns to be identical to that of disopyramide under various chromatographic conditions, as did Kelly et al. (18) . Disopyramide probably will be used in combination with mexiletine for control of arrhythmias (20) . Symptoms of toxicity (including tremor, nystagmus, nausea, vomiting, confusion, bradycardia, and hypotension) are said to be associated with concentrations exceeding 2.0 mg/L in serum (7, 8) ; we agree.
The mexiletine procedure described in this paper is a practical clinical method that has been in routine use in our laboratory for more than six months in support of a clinical trial of mexiletine.
